<DOC>
	<DOC>NCT02880631</DOC>
	<brief_summary>The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.</brief_summary>
	<brief_title>BAROSTIM THERAPYâ„¢ In Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Has signed an EC approved informed consent form Has been implanted with the BAROSTIM NEO system in the past 30 days Systolic blood pressure greater than or equal to 140 mmHg, and Resistance to maximally tolerated therapy with a diuretic and two other antihypertension medications Bilateral carotid bifurcations located above the level of the mandible Baroreflex failure or autonomic neuropathy Uncontrolled, symptomatic cardiac bradyarrhythmias Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>